Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 459052, 9 pages
http://dx.doi.org/10.1155/2015/459052
Research Article

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

Department of Hematology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China

Received 13 August 2014; Accepted 31 August 2014

Academic Editor: Fenghuang Zhan

Copyright © 2015 Lu Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Genadieva-Stavric, F. Cavallo, and A. Palumbo, “New approaches to management of multiple myeloma,” Current Treatment Options in Oncology, vol. 15, no. 2, pp. 157–170, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. X.-Y. Pei, Y. Dai, and S. Grant, “Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors,” Clinical Cancer Research, vol. 10, no. 11, pp. 3839–3852, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Weber, T. Graef, M. Hussein et al., “Phase i trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma,” Clinical Lymphoma, Myeloma and Leukemia, vol. 12, no. 5, pp. 319–324, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fostier, A. de Becker, and R. Schots, “Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma,” OncoTargets and Therapy, vol. 5, pp. 237–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Moreau, “The emerging role of carfilzomib combination therapy in the management of multiple myeloma,” Expert Review of Hematology, vol. 7, no. 2, pp. 265–290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. Berenson, J. D. Hilger, O. Yellin et al., “Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy,” Leukemia, vol. 28, no. 7, pp. 1529–1536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Neri, N. J. Bahlis, and S. Lonial, “Panobinostat for the treatment of multiple myeloma,” Expert Opinion on Investigational Drugs, vol. 21, no. 5, pp. 733–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Khot, M. Dickinson, and H. M. Prince, “Panobinostat in lymphoid and myeloid malignancies,” Expert Opinion on Investigational Drugs, vol. 22, no. 9, pp. 1211–1223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. San-Miguel, P. G. Richardson, A. Günther et al., “Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma,” Journal of Clinical Oncology, vol. 31, no. 29, pp. 3696–3703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Berenson, J. D. Hilger, O. Yellin et al., “A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma,” Annals of Hematology, vol. 93, no. 1, pp. 89–98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. P. G. Richardson, R. L. Schlossman, M. Alsina et al., “PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma,” Blood, vol. 122, no. 14, pp. 2331–2337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Feng, A. Oton, M. Y. Mapara, G. Anderson, C. Belani, and S. Lentzsch, “The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage,” The British Journal of Haematology, vol. 139, no. 3, pp. 385–397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Hideshima, J. E. Bradner, J. Wong et al., “Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8567–8572, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Bhalla, S. Balasubramanian, K. David, and et al, “PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF- κB mechanisms and is synergistic with bortezomib in lymphoma cells,” Clinical Cancer Research, vol. 15, no. 14, pp. 3354–3365, 2009. View at Google Scholar
  15. R. Castelli, R. Gualtierotti, N. Orofino, A. Losurdo, S. Gandolfi, and M. Cugno, “Current and emerging treatment options for patients with relapsed myeloma,” Clinical Medicine Insights: Oncology, vol. 7, pp. 209–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Bastian, J. Hof, M. Pfau et al., “Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB,” Clinical Cancer Research, vol. 19, no. 6, pp. 1445–1457, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Fribley, Q. Zeng, and C.-Y. Wang, “Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells,” Molecular and Cellular Biology, vol. 24, no. 22, pp. 9695–9704, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. Y.-H. Ling, L. Liebes, Y. Zou, and R. Perez-Soler, “Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 Non-small cell lung cancer cells,” The Journal of Biological Chemistry, vol. 278, no. 36, pp. 33714–33723, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. R. R. Rosato, S. S. Kolla, S. K. Hock et al., “Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway,” The Journal of Biological Chemistry, vol. 285, no. 13, pp. 10064–10077, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Ungerstedt, Y. Sowa, W.-S. Xu et al., “Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 673–678, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Gao, L. Gao, Y. Tao et al., “Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells,” Acta Biochimica et Biophysica Sinica, vol. 46, no. 6, pp. 484–491, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Dasmahapatra, D. Lembersky, M. P. Son et al., “Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 10, no. 9, pp. 1686–1697, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Wang, J. L. Martindale, Y. Liu, and N. J. Holbrook, “The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival,” The Biochemical Journal, vol. 333, no. part 2, pp. 291–300, 1998. View at Google Scholar · View at Scopus
  24. Q.-L. Zhang, L. Wang, Y.-W. Zhang et al., “The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis,” Leukemia, vol. 23, no. 8, pp. 1507–1514, 2009. View at Publisher · View at Google Scholar · View at Scopus